Risk factor
Resilient to price shocks
Profitability factor
Very poor margins and returns
About
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent products, and related diagnostic kits, including matrix metalloproteinase 3, IV collagen, adiponectin, creatine kinase isoenzyme, hepatic bile acid, cardiac troponin I, heparin binding protein, hemoglobin A1C, lipoprotein phospholipase A2, heart fatty acid binding protein, ferritin, sialoglycoside antigen, and procalcitonin kits. The Oral Tissue Repair and Regeneration Materials segment provides oral bone repair materials, implant systems, natural bone repair materials, oral restorative films, collagen-based bone repair matrices, and soft tissue repair matrices, primarily for dental implantation and maxillofacial bone defect repair. The company was founded in 1981 and is headquartered in Shanghai, China.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overvalued on P/FCF.